Noven Provides Update on Daytrana(R) Methylphenidate Transdermal System (Busi bi13160764 MIAMI----Noven Pharmaceuticals, Inc. today provided an update on the status of Daytrana®, the only transdermal patch indicated for the treatment of the symptoms of Attention Deficit Hyperactivity Disorder

Xel Pharmaceuticals' Successful Completion Of Prototype Once-A-Week Huperzine bi13160764 Xel Pharmaceuticals, Inc. announced the completion of the development of once-a-week Huperzine A transdermal patch for the treatment of Alzheimer's disease (AD). The prototype transdermal patch can deliver 400-800 mcg of Huperzine A per day for up to seven days

Xel completes development of prototype transdermal patch for Alzheimer's (Pha bi13160764 Xel Pharmaceuticals has completed the development of once-a-week Huperzine A transdermal patch for the treatment of Alzheimers disease. The prototype transdermal patch can deliver 400?800mcg of Huperzine A per day for up to seven days

Xel Pharmaceuticals Announces Successful Completion of Prototype Once-A-Week bi13160764 Xel Pharmaceuticals, Inc. announced today the completion of the development of once-a-week Huperzine A transdermal patch for the treatment of Alzheimer's disease (AD). The prototype transdermal patch can deliver 400-800 mcg of Huperzine A per day for up to seven days. Huperzine A a naturally occurring alkaloid found from the club moss Huperzia serrata that has been used for decades ..

Xel Pharmaceuticals Announces Successful Completion of Prototype Once-A-Week bi13160764 DRAPER, Utah----Xel Pharmaceuticals, Inc. announced today the completion of the development of once-a-week Huperzine A transdermal patch for the treatment of Alzheimer's disease

Alternative Drug Delivery Systems Key For European hGH Market (Pharmaceutical bi13160764 With the approval of biosimilars Europe, the overall cost of human growth hormone (hGH) treatment has reduced by more than 25 per cent

Alternative Drug Delivery Systems Key for European hGH Market (Business Wire bi13160764 LONDON----With the approval of biosimilars Europe, the overall cost of human growth hormone treatment has reduced by more than 25 per cent. Manufacturers are now more likely to take initiatives to obtain marketing approval from EMEA for other indications and to increase research alternative drug methods to combat pricing pressures from biosimilars

Altea Theraupeutics' Steven Damon Featured As Industry Leader At BioNetwork 2 bi13160764 Steven Damon leads the Business Development Team for Altea Therapeutics. Damon present the company's unique partnership opportunities at BioNetwork's Metabolic Diseases Partnering Primer, on October 7, 2008

Dutton Associates Announces Investment Opinion: Vyteris Rating Speculative Bu bi13160764 Dutton Associates updates coverage of Vyteris (OTCBB:VYTR) maintaining a Speculative Buy rating and a $1 price target. The 13-page report by Dutton senior analyst Richard W. West, CFA available at www.jmdutton.com as well as from First Call, Bloomberg Professional, FactSet, Capital IQ, Zacks, Reuters, Knobias, and other leading financial portals

Dutton Associates Announces Investment Opinion: Vyteris Rating Speculative Bu bi13160764 ROSEVILLE, Calif.----Dutton Associates updates coverage of Vyteris maintaining a Speculative Buy rating and a $1 price target. The 13-page report by Dutton senior analyst Richard W

Sealed Air Corporation Deploys Blue Spark Thin Printed Batteries To Power Its bi13160764 CLEVELAND----Blue Spark Technologies, the leading supplier of thin, flexible printed battery solutions, announced today that Sealed Air Corporation selected Blue Spark thin, flexible batteries as a core component of TurboTag? RFID-enabled time and temperature monitoring and data logging solution

Antares Pharma Enters Into a Feasibility Development Agreement Dr. Reddy bi13160764 EWING, N.J.----Antares Pharma, Inc. a specialty pharmaceutical company focused on improving pharmaceuticals through advanced drug systems, today announced that they have entered a development agreement Dr

Antares Pharma Enters Into A Feasibility Development Agreement With Dr. Reddy bi13160764 Antares Pharma, Inc. today announced that they have entered a development agreement Dr. Reddy's Laboratories, Inc. for the development of an innovative, topically applied product, using Antares' ATD Gel platform, targeting specific receptor sites the skin

Stew Beef Recipes - Home